Pertuzumab plus trastuzumab and chemotherapy for Japanese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subgroup analysis of the JACOB trial

被引：0
|
作者：
Kohei Shitara
Hiroki Hara
Takaki Yoshikawa
Kazumasa Fujitani
Tomohiro Nishina
Ayumu Hosokawa
Takashi Asakawa
Satoe Kawakami
Kei Muro
机构：
[1] National Cancer Center Hospital East,Gastroenterology and Gastrointestinal Oncology
[2] Saitama Cancer Center,Department of Gastroenterology
[3] Kanagawa Cancer Center,Department of Gastrointestinal Surgery
[4] National Cancer Center Hospital,Department of Gastric Surgery
[5] Osaka General Medical Center,Department of Surgery
[6] National Hospital Organization Shikoku Cancer Center,Department of Gastrointestinal Medical Oncology
[7] University of Toyama,Department of Gastroenterology and Hematology, Faculty of Medicine
[8] University of Miyazaki Hospital,Department of Clinical Oncology
[9] Chugai Pharmaceutical Co.,Clinical Information and Intelligence Department
[10] Ltd,Clinical Science & Strategy Department
[11] Chugai Pharmaceutical Co.,Department of Clinical Oncology
[12] Ltd,undefined
[13] Aichi Cancer Center Hospital,undefined
来源：
International Journal of Clinical Oncology | 2020年 / 25卷
关键词：
Pertuzumab; Trastuzumab; Metastatic gastric cancer; Metastatic gastroesophageal junction cancer; Japanese subgroup analysis; Phase III;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：301 / 311
页数：10
相关论文
共 50 条
  • [31] Trastuzumab in combination with chemotherapy for HER2-positive metastatic gastric cancer patients underwent conversion therapy
    Zhang, Yanqiang
    Xu, Xiaoqing
    Hu, Can
    Du, Yian
    Ding, Guangyu
    Chen, Jiahui
    Zhu, Xiu
    Xu, Zhiyuan
    Wei, Qing
    TRANSLATIONAL CANCER RESEARCH, 2022, 11 (07) : 2145 - 2156
  • [32] Complete response after "neoadjuvant" pertuzumab plus trastuzumab plus docetaxel chemotherapy in Her2-positive breast cancer
    Lai-Tiong, F.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2018, 39 (05) : 836 - 837
  • [33] Comparing pyrotinib with trastuzumab and pertuzumab with trastuzumab for HER2-positive metastatic breast cancer: a retrospective, multicenter analysis
    You, Shuhui
    Xie, Yizhao
    Sang, Die
    Luo, Ting
    Yuan, Peng
    Xu, Fei
    Wang, Biyun
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [34] Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
    Veeraraghavan, Jamunarani
    Gutierrez, Carolina
    Sethunath, Vidyalakshmi
    Mehravaran, Sepideh
    Giuliano, Mario
    Shea, Martin J.
    Mitchell, Tamika
    Wang, Tao
    Nanda, Sarmistha
    Pereira, Resel
    Davis, Robert
    Goutsouliak, Kristina
    Qin, Lanfang
    De Angelis, Carmine
    Diala, Irmina
    Lalani, Alshad S.
    Nagi, Chandandeep
    Hilsenbeck, Susan G.
    Rimawi, Mothaffar F.
    Osborne, C. Kent
    Schiff, Rachel
    NPJ BREAST CANCER, 2021, 7 (01)
  • [35] Costs of Trastuzumab in Combination With Chemotherapy for HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: An Economic Evaluation in the Chinese Context
    Wu, Bin
    Ye, Ming
    Chen, Huafeng
    Shen, Jinfang F.
    CLINICAL THERAPEUTICS, 2012, 34 (02) : 468 - 479
  • [36] Pertuzumab plus trastuzumab for HER2-positive metastatic biliary cancer: Preliminary data from MyPathway.
    Javle, Milind M.
    Hainsworth, John D.
    Swanton, Charles
    Burris, Howard A.
    Kurzrock, Razelle
    Sweeney, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [37] Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
    Jamunarani Veeraraghavan
    Carolina Gutierrez
    Vidyalakshmi Sethunath
    Sepideh Mehravaran
    Mario Giuliano
    Martin J. Shea
    Tamika Mitchell
    Tao Wang
    Sarmistha Nanda
    Resel Pereira
    Robert Davis
    Kristina Goutsouliak
    Lanfang Qin
    Carmine De Angelis
    Irmina Diala
    Alshad S. Lalani
    Chandandeep Nagi
    Susan G. Hilsenbeck
    Mothaffar F. Rimawi
    C. Kent Osborne
    Rachel Schiff
    npj Breast Cancer, 7
  • [38] Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
    Bianchini, Giampaolo
    Kiermaier, Astrid
    Bianchi, Giulia Valeria
    Im, Young-Hyuck
    Pienkowski, Tadeusz
    Liu, Mei-Ching
    Tseng, Ling-Ming
    Dowsett, Mitch
    Zabaglo, Lila
    Kirk, Sarah
    Szado, Tania
    Eng-Wong, Jennifer
    Amler, Lukas C.
    Valagussa, Pinuccia
    Gianni, Luca
    BREAST CANCER RESEARCH, 2017, 19
  • [39] Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
    Giampaolo Bianchini
    Astrid Kiermaier
    Giulia Valeria Bianchi
    Young-Hyuck Im
    Tadeusz Pienkowski
    Mei-Ching Liu
    Ling-Ming Tseng
    Mitch Dowsett
    Lila Zabaglo
    Sarah Kirk
    Tania Szado
    Jennifer Eng-Wong
    Lukas C. Amler
    Pinuccia Valagussa
    Luca Gianni
    Breast Cancer Research, 19
  • [40] Pharmacokinetic (PK) and exposure-response (ER) analysis of pertuzumab (P) in patients (pts) with HER2-positive metastatic gastroesophageal junction and gastric cancer (mGEJC/GC).
    Kirschbrown, Whitney Paige
    Wang, Bei
    Nijem, Ihsan
    Ohtsu, Atsushi
    Hoff, Paulo M.
    Shah, Manish A.
    Shen, Lin
    Kang, Yoon-Koo
    Tabernero, Josep
    Girish, Sandhya
    Garg, Amit
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345